Skip to main content
. Author manuscript; available in PMC: 2014 Apr 8.
Published in final edited form as: Exp Neurol. 2009 Sep 4;220(1):191–197. doi: 10.1016/j.expneurol.2009.08.028

Fig. 4.

Fig. 4

The effect of lenalidomide treatment from onset of ALS on survival in G93A SOD1 mice. (A) The cumulative (Cum.) probability of survival for G93A mice treated from disease onset with lenalidomide (100 mg/kg/day) shows significantly higher (**P<0.01) Mental–Cox, logrank. The duration from age of onset to death is significantly extended by 44.3% (P<0.001). Values are mean±SD. (B) The average length of survival time shown in histogram. The G93A SOD1 mice treated with lenalidomide (n=18) survived significantly longer from the age of onset as compared to untreated G93A littermate controls (n=18). **P<0.01.